We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amphastar Slow to Report SAEs, Form 483 States
Amphastar Slow to Report SAEs, Form 483 States
October 1, 2012
Amphastar Pharmaceuticals is slow to notify the FDA about complaints of serious and/or unexpected adverse events associated with its various generic drug products, a Form 483 states.